Browsing Tag
Neuren Pharmaceuticals Limited
2 posts
Neuren Pharmaceuticals (ASX: NEU) begins first-ever Phase 3 trial in Phelan-McDermid syndrome
Neuren Pharmaceuticals Limited has dosed the first patient in the first Phase 3 Phelan-McDermid syndrome trial. See why it matters for rare disease drug development.
ACADIA Pharmaceuticals stock surges 26% after key patent win and robust Q1 results: What’s driving investor optimism?
Find out why ACADIA Pharmaceuticals stock soared 26% on May 16, 2025, after a favorable court ruling and strong earnings—plus what’s next for its CNS pipeline.